Released Mar 11, 2021, after the close
10-K filed Mar 11, 2021, 70 days after period end · 0001493152-21-005827
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.18M$1.18M derived−77.3% vs Q4 2019−20.4% vs Q3 2020
Net Income-$2.22M-$2.22M derivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,206,679N/M
Operating Cash Flowderived-$1,637,715N/M
Free Cash Flowderived-$1,650,538N/M
Margins · derived
Operating margin-187.8%−164.1 pt vs Q4 2019
Net margin-188.8%−163.8 pt vs Q4 2019
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.18M | $5.17M | $5.92M | $5.30M |
| Net Income | -$2.22M | -$1.29M | $52.00K | -$639.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR